Genital Herpes Remedies: Why Did the FDA Warn Retailers?

Why is the FDA warning about online genital herpes remedies?

In an October 1 warning letter, the FDA identified creams, ointments, sprays and a wash purchased through Amazon that were marketed for genital herpes or associated symptoms without the required approval. Products named included FemiClear, HerpCare Spray and RoyceDerm Herpes Relief Cream. The agency emphasized that no over-the-counter drug has FDA approval to treat, cure, mitigate or prevent a sexually transmitted infection. [FDA warning letter to Amazon](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/amazoncom-inc-736006-10012026).

A separate letter to Walmart named HClear for him, Herstat GST and Terragen HG Formula. The FDA requested a response describing corrective measures within 15 business days of receipt. Its concern extends beyond product labeling: people who believe an infection has been adequately treated may postpone medical care or unknowingly transmit it. These letters document regulatory findings and potential risks; they do not establish how many customers experienced harm. [FDA warning letter to Walmart](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/walmart-inc-736557-10012026).

Which treatments actually help control genital herpes?

Herpes simplex virus remains inside nerve cells and can reactivate after periods without symptoms. This explains why healing sores does not mean the infection has disappeared. WHO identifies acyclovir, valacyclovir and famciclovir as commonly used antiviral medicines that reduce the duration or severity of symptoms. Treatment can make herpes manageable, although it does not provide a cure. [WHO herpes simplex virus fact sheet](https://www.who.int/news-room/fact-sheets/detail/herpes-simplex-virus).

CDC guidance distinguishes treatment taken for an outbreak from daily suppressive therapy. For people with frequent recurrent genital HSV-2, suppression reduces recurrence frequency by 70–80%; that figure describes fewer outbreaks, not a comparable reduction in transmission. Episodic treatment works best when started during warning symptoms or within one day of lesions appearing. CDC recommends antiviral treatment for a first clinical episode and discourages topical antiviral therapy because its clinical benefit is small. A clinician can help select an approach based on symptoms and preferences. [CDC genital herpes treatment guidelines](https://www.cdc.gov/std/treatment-guidelines/herpes.htm).

What should people do if they have symptoms or used these products?

New genital sores, burning during urination or unusual discharge deserve assessment rather than self-diagnosis from a product listing. Herpes symptoms can be mild or mistaken for another skin condition. A clinician may take a sample from a sore for testing; blood testing can sometimes help, but it cannot establish when an infection began or who transmitted it. Bring the product name and ingredient list to the appointment so the clinician can review what you have used. [CDC information on genital herpes](https://www.cdc.gov/herpes/about/index.html).

While symptoms are present, avoid sexual contact involving the affected area. Condoms reduce transmission risk but cannot cover every area of potentially infectious skin, and herpes can spread without visible sores. Pregnancy and weakened immunity make timely advice especially important: infection acquired late in pregnancy carries a greater risk to the newborn, while immunocompromised people can experience more severe disease. These risks support prompt, individualized care without implying that every outbreak is dangerous. [WHO guidance on herpes transmission and complications](https://www.who.int/news-room/fact-sheets/detail/herpes-simplex-virus).